600 MADISON AVENUE, SUITE 1601, NEW YORK, NY
Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
Amended material disclosure
Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
Investor Presentation
iBio, Inc. Enters Open Market Sale Agreement with Jefferies LLC
Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
$26 Million Private Placement
Q3
Q2
Amended Quarterly Report
Q1
FY 2025
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload